Dearborn Partners LLC Sells 305 Shares of Sanofi (NASDAQ:SNY)

Dearborn Partners LLC trimmed its position in shares of Sanofi (NASDAQ:SNY) by 5.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,416 shares of the company’s stock after selling 305 shares during the period. Dearborn Partners LLC’s holdings in Sanofi were worth $300,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of SNY. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Sanofi by 124.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company’s stock worth $1,344,000 after purchasing an additional 13,358 shares in the last quarter. Axxcess Wealth Management LLC grew its holdings in Sanofi by 130.5% during the 1st quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company’s stock valued at $568,000 after buying an additional 5,794 shares in the last quarter. Ballentine Partners LLC grew its holdings in Sanofi by 68.7% during the 1st quarter. Ballentine Partners LLC now owns 26,063 shares of the company’s stock valued at $1,445,000 after buying an additional 10,617 shares in the last quarter. Sowell Financial Services LLC bought a new stake in shares of Sanofi during the first quarter valued at approximately $328,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Sanofi by 66.2% in the first quarter. Farther Finance Advisors LLC now owns 6,215 shares of the company’s stock worth $338,000 after buying an additional 2,476 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Analysts Set New Price Targets

SNY has been the subject of several research analyst reports. Hsbc Global Res raised shares of Sanofi to a “strong-buy” rating in a research note on Monday, April 28th. BNP Paribas started coverage on Sanofi in a research report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 price objective for the company. Barclays reiterated an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Morgan Stanley set a $56.00 price target on Sanofi in a report on Monday, June 2nd. Finally, Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Three analysts have rated the stock with a hold rating, three have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $62.00.

Sanofi Stock Down 0.2%

Shares of NASDAQ:SNY opened at $49.25 on Thursday. The company has a market cap of $120.78 billion, a price-to-earnings ratio of 17.59, a PEG ratio of 1.13 and a beta of 0.48. Sanofi has a 12 month low of $45.80 and a 12 month high of $60.12. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The company has a 50-day moving average price of $49.34 and a 200 day moving average price of $52.11.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.